The new ADC product candidates will be used by OXIS to treat triple-negative breast cancer, and multiple myeloma and associated osteolytic lesions which are significant unmet medical needs.
In March 2015, Boehringer filed a Paragraph IV lawsuit against Breckenridge in the US District Court for the District of New Jersey, in return Breckenridge filed its Paragraph
The 15-week double-blind, randomized, placebo-controlled Phase IV trial enrolled a total of 107 adolescent patients from multiple centers across the US, Europe and Asia. This is the first
The company said that the original NDA has been amended to include data from the Phase III ALLY-3 trial, which tested a 12-week, ribavirin-free regimen and resulted in
The drug has been approved for use in combination with chlorambucil chemotherapy to treat adults with chronic lymphotic leukaemia (CLL). Gazyvaro is indicated to treat adults who are
LNA oligos offer dramatically improved sensitivity and specificity compared to traditional DNA chemistries. The amended agreement provides the company with access to LNA oligos for use with all
Pembrolizumab is marketed in the US under the name Keytruda. EAMS was introduced by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in 2014 to help patients
In October 2010, the Japanese firm entered into an agreement with the Japan Health HS Foundation for the development of the HPV vaccine to prevent cervical cancer. Subsequently,
Lpathomab is a new antibody targeting Lysophosphatidic Acid (LPA), a bioactive lipid that has been characterized in the scientific literature as playing a major role in nerve injury
Endo said it would pay $175 per Salix share, which will include 1.4607 of its shares plus $45 in cash. Earlier in February, Canada-based Valeant Pharmaceuticals signed an
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.